AI Article Synopsis

  • Pancreatic cancer has a very poor prognosis, primarily due to tumor hypoxia, which is a lack of oxygen in the tumor environment.
  • Targeting tumor hypoxia is seen as a promising therapeutic strategy, but past efforts have not achieved clinical success.
  • A new compound, NMP-BE@SAC5A, has been developed that effectively targets hypoxic pancreatic cancer cells and has shown significant tumor growth suppression in animal models without causing systemic toxicity.

Article Abstract

The prognosis with pancreatic cancer is among the poorest of any human cancer. One of the important factors is the tumor hypoxia. Targeting tumor hypoxia is considered a desirable therapeutic option. However, it has not been translated into clinical success in the treatment of pancreatic cancer. With enhanced cytotoxicities against hypoxic pancreatic cancer cells, BE-43547A2 (BE) may serve as a promising template for hypoxia target strategy. Here, based on rational modification, a BE prodrug (NMP-BE) is encapsulated into sulfonated azocalix[5]arene (SAC5A) to generate a supramolecular dual hypoxia-responsive complex NMP-BE@SAC5A. Benefited from the selective load release within cancer cells, NMP-BE@SAC5A markedly suppresses tumor growth at low dose in pancreatic cancer cells xenograft murine model without developing systemic toxicity. This research presents a strategy for the modification of covalent compounds to achieve efficient delivery within tumors, a horizon for the realization of safe and reinforced hypoxia target therapy using a simple approach.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500001PMC
http://dx.doi.org/10.1038/s41467-023-41388-2DOI Listing

Publication Analysis

Top Keywords

pancreatic cancer
16
cancer cells
12
dual hypoxia-responsive
8
target therapy
8
tumor hypoxia
8
hypoxia target
8
cancer
7
hypoxia-responsive supramolecular
4
supramolecular complex
4
complex cancer
4

Similar Publications

Risk factors for delayed gastric emptying after pancreatoduodenectomy: a 10-year retrospective study.

Ann Med

December 2025

Department of Surgery, Faculty of Medicine, Unit of Hepato-Pancreato-Biliary Surgery and Abdominal Organ Transplantation, Doce de Octubre University Hospital, Instituto de Investigación (imas12), Complutense University, Madrid, Spain.

Background: Delayed gastric emptying (DGE) is a frequent complication of pancreatoduodenectomy (PD) and is associated with prolonged hospital stay, readmission, increased hospital costs and decreased quality of life. However, the pathophysiology of DGE remains unclear.

Methods: This is a retrospective study of patients who underwent PD for pancreatic or periampullary tumours.

View Article and Find Full Text PDF

Background And Purpose: Radiation-induced lymphopenia (RIL) may be associated with a worse prognosis in pancreatic cancer. This study aimed to develop a normal tissue complication probability (NTCP) model to predict severe RIL in patients with pancreatic cancer undergoing concurrent chemoradiotherapy (CCRT).

Materials And Methods: We reviewed pancreatic cancer patients treated at our facility for model training and internal validation.

View Article and Find Full Text PDF

Cell type-specific upregulation of NKG2D ligand MICA in response to APTO253.

Ann Transl Med

December 2024

Institute for Tumor Immunology, Center for Tumor Biology and Immunology, Philipps-University Marburg, Marburg, Germany.

One of the most important targets for natural killer (NK) cell-mediated therapy is the induction of natural killer group 2D ligand (NKG2D-L) expression. APTO253 is a small molecule that selectively kills acute myeloid leukemia (AML) cells, and it has been reported that APTO253 can induce Krüppel-like factor 4 (KLF4) expression and downregulate c-MYC expression. Recently, we discovered a novel role of APTO253 in modulating the NK cell response by inducing surface expression of NKG2D-Ls, especially MHC class I polypeptide-related sequence A (MICA), in AML cells.

View Article and Find Full Text PDF

Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive lethal malignancy with limited options for treatment and a 5-year survival rate of 11% in the United States. As for other types of tumors, such as colorectal cancer, aberrant lipid synthesis and reprogrammed lipid metabolism have been suggested to be associated with PDAC development and progression.

Aim: To identify the possible involvement of lipid metabolism in PDAC by analyzing in tumoral and non-tumoral tissues the expression level of the most relevant genes involved in the long-chain fatty acid (FA) import into cell.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!